- Conditions
- Brain Tumor - Metastatic
- Interventions
- Carmustine 7.7Mg Wafer
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ADHD
- Interventions
- AR08, Placebo
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 13
- States / cities
- Brandenton, Florida • Jacksonville, Florida • North Miami, Florida + 9 more
- Conditions
- Alcohol Use Disorder
- Interventions
- gabapentin enacarbil, Placebo
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 7 more
- Conditions
- Abuse Potential
- Interventions
- Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy
- Interventions
- Isosorbide dinitrate / hydralazine capsules
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Heart Failure
- Interventions
- BiDil XR, BiDil Immediate Release (IR)
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Coral Gables, Florida • Jacksonville, Florida + 2 more
- Conditions
- Pain, Otitis Media
- Interventions
- benzocaine, placebo
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Months to 4 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 15
- States / cities
- Jonesboro, Arkansas • Miami Beach, Florida • West Des Moines, Iowa + 11 more
- Conditions
- Acute Otitis Media
- Interventions
- AR01, Placebo Comparator
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Months to 18 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fresno, California + 16 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Amphetamine Sulfate, Placebo
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 31
- States / cities
- Encino, California • Garden Grove, California • Newport Beach, California + 26 more
- Conditions
- Hypertension
- Interventions
- Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg)
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more
- Conditions
- Acute Otitis Media
- Interventions
- AR01, Glycerin ear drops
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Months to 18 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 29
- States / cities
- Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- AR11, Placebo
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 7
- States / cities
- Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more
- Conditions
- Anesthesia
- Interventions
- AR09 solution, placebo
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Abuse Potential
- Interventions
- Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- CNS Tumor
- Interventions
- Not listed
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Scottdale, Arizona + 28 more
- Conditions
- Vasomotor Symptoms (VMS)
- Interventions
- AR08, Placebo
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 41 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 15
- States / cities
- San Diego, California • Colorado Springs, Colorado • Lakeworth, Florida + 11 more